VLTS-589 consists of plasmid encoding the angiomatrix protein Del-1 in conjunction with poloxamer 188 for the treatment of peripheral vascular disease.
- Mechanism
- Curator reviewed
VLTS-589 is an investigational nonviral therapeutic comprising a plasmid-expressing Del-1 formulated with poloxamer 188 (facilitating agent). Del-1 plasmid-polaxamer enhances gene transfer at doses that are an order of magnitude different than other comparable trials in a unique bilateral intramuscular dosing pattern to maximize transfection/clinical efficacy and general applicability to patients with peripheral arterial disease (PAD).
- Primary indication
- Investigated for use/treatment in peripheral vascular disease.Curator reviewed
- Code names
- VLTS-589
What you can answer from here — as of September 25, 2025
Which companies are running trials of VLTS-589, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account